Biologics CDMOs provide specialist services for developing and manufacturing biopharmaceuticals—such as monoclonal antibodies, vaccines, recombinant proteins, cell & gene therapies. Pharma and biotech firms outsource to CDMOs to accelerate development, manage complex large-molecule production, ensure regulatory compliance, and scale up efficiently. Market growth is driven by increasing biologics pipelines, rising demand for biosimilars, advances in single-use technologies, and expansion of global biomanufacturing infrastructure. Key challenges include high capital costs, maintaining quality across global sites, and ensuring supply chain resilience.